moderate - While healthcare spending is relatively defensive, capital equipment purchases by hospitals and wound care centers exhibit cyclical sensitivity during economic downturns when facility budgets tighten. However, diabetic foot ulcer prevalence (driven by diabetes epidemic) provides stable underlying demand. The company's early commercialization stage means adoption is more dependent on clinical validation and reimbursement than macro conditions.

Rising interest rates negatively impact SANUWAVE through multiple channels: higher cost of capital for a cash-burning company requiring ongoing financing, compressed valuation multiples for unprofitable growth companies, and reduced hospital capital budgets as borrowing costs increase for facility equipment purchases. The negative debt/equity ratio (-8.34) suggests complex capital structure potentially involving convertible instruments sensitive to equity volatility.

Speculative growth/biotech investors seeking asymmetric upside from potential reimbursement inflection or acquisition by larger medtech player. The -24% 3-month and -33.5% 6-month returns indicate high-risk, binary outcome profile typical of pre-commercial medical device companies. Not suitable for value or income investors given negative profitability and no dividend. Attracts momentum traders around clinical/regulatory catalysts.